TrialThe New England journal of medicine2023
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
Mansoor R Mirza et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
429 papers cite itlatest 60 shown
this paperpooled ittrialcites it